Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase

A multicenter retrospective study

Alex Zvulunov, Catherine McCuaig, Ilona J. Frieden, Anthony J. Mancini, Katherine Brown Puttgen, Magdalene Dohil, Gayle Fischer, Julie Powell, Bernard A Cohen, Dan Ben Amitai

Research output: Contribution to journalArticle

Abstract

Pharmacological therapies for infantile hemangiomas were considered effective only during the proliferative phases. Recently reported beneficial effects of propranolol may extend beyond the proliferative phase of infantile hemangiomas. The purpose of the study was to assess the effect of oral propranolol therapy for infantile hemangiomas beyond the proliferative phase of these lesions. Members of the Society for Pediatric Dermatology were invited to participate in a multicenter retrospective study. Only children with infantile hemangiomas with documented cessation of lesions' growth or those older than 12 months of age were eligible for the study. Clinical and demographic information and digital photographs before, at the start, and following the treatment were collected. Scaled panels of photographs were distributed among preselected experienced pediatric dermatologists. Visual analog scale was used to assess photographs for each case. Paired t-test was used for statistical analyses. Data on 49 eligible patients from eight pediatric dermatology centers was collected. Seven cases were excluded because of insufficient photographic documentation. The age of the patients at the start of propranolol therapy ranged 7 to 120 months (mean 28 mos, median 22 mos). The duration of propranolol therapy ranged 1 to 8 months (mean 3.6 mos). The mean visual analog scale score before the treatment was 6.8 ± 2.15, and mean reduction in the visual analog scale score at the assessment was 2.6 ± 1.74 (p <0.001). The rate of visual analog scale reduction was 0.4 per month before the start of the therapy, while this rate was accelerated to 0.9 per months following the therapy (p <0.001). No significant side effects were reported. We conclude that propranolol is effective in infantile hemangiomas, including post-proliferative phase, and should be considered as the first-line therapy in that setting.

Original languageEnglish (US)
Pages (from-to)94-98
Number of pages5
JournalPediatric Dermatology
Volume28
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Hemangioma
Propranolol
Multicenter Studies
Retrospective Studies
Visual Analog Scale
Therapeutics
Pediatrics
Only Child
Dermatology
Documentation
Demography
Pharmacology
Growth

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Zvulunov, A., McCuaig, C., Frieden, I. J., Mancini, A. J., Puttgen, K. B., Dohil, M., ... Amitai, D. B. (2011). Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: A multicenter retrospective study. Pediatric Dermatology, 28(2), 94-98. https://doi.org/10.1111/j.1525-1470.2010.01379.x

Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase : A multicenter retrospective study. / Zvulunov, Alex; McCuaig, Catherine; Frieden, Ilona J.; Mancini, Anthony J.; Puttgen, Katherine Brown; Dohil, Magdalene; Fischer, Gayle; Powell, Julie; Cohen, Bernard A; Amitai, Dan Ben.

In: Pediatric Dermatology, Vol. 28, No. 2, 03.2011, p. 94-98.

Research output: Contribution to journalArticle

Zvulunov, A, McCuaig, C, Frieden, IJ, Mancini, AJ, Puttgen, KB, Dohil, M, Fischer, G, Powell, J, Cohen, BA & Amitai, DB 2011, 'Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: A multicenter retrospective study', Pediatric Dermatology, vol. 28, no. 2, pp. 94-98. https://doi.org/10.1111/j.1525-1470.2010.01379.x
Zvulunov, Alex ; McCuaig, Catherine ; Frieden, Ilona J. ; Mancini, Anthony J. ; Puttgen, Katherine Brown ; Dohil, Magdalene ; Fischer, Gayle ; Powell, Julie ; Cohen, Bernard A ; Amitai, Dan Ben. / Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase : A multicenter retrospective study. In: Pediatric Dermatology. 2011 ; Vol. 28, No. 2. pp. 94-98.
@article{fac12a4bf8e54089b60d38dd796a44d1,
title = "Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: A multicenter retrospective study",
abstract = "Pharmacological therapies for infantile hemangiomas were considered effective only during the proliferative phases. Recently reported beneficial effects of propranolol may extend beyond the proliferative phase of infantile hemangiomas. The purpose of the study was to assess the effect of oral propranolol therapy for infantile hemangiomas beyond the proliferative phase of these lesions. Members of the Society for Pediatric Dermatology were invited to participate in a multicenter retrospective study. Only children with infantile hemangiomas with documented cessation of lesions' growth or those older than 12 months of age were eligible for the study. Clinical and demographic information and digital photographs before, at the start, and following the treatment were collected. Scaled panels of photographs were distributed among preselected experienced pediatric dermatologists. Visual analog scale was used to assess photographs for each case. Paired t-test was used for statistical analyses. Data on 49 eligible patients from eight pediatric dermatology centers was collected. Seven cases were excluded because of insufficient photographic documentation. The age of the patients at the start of propranolol therapy ranged 7 to 120 months (mean 28 mos, median 22 mos). The duration of propranolol therapy ranged 1 to 8 months (mean 3.6 mos). The mean visual analog scale score before the treatment was 6.8 ± 2.15, and mean reduction in the visual analog scale score at the assessment was 2.6 ± 1.74 (p <0.001). The rate of visual analog scale reduction was 0.4 per month before the start of the therapy, while this rate was accelerated to 0.9 per months following the therapy (p <0.001). No significant side effects were reported. We conclude that propranolol is effective in infantile hemangiomas, including post-proliferative phase, and should be considered as the first-line therapy in that setting.",
author = "Alex Zvulunov and Catherine McCuaig and Frieden, {Ilona J.} and Mancini, {Anthony J.} and Puttgen, {Katherine Brown} and Magdalene Dohil and Gayle Fischer and Julie Powell and Cohen, {Bernard A} and Amitai, {Dan Ben}",
year = "2011",
month = "3",
doi = "10.1111/j.1525-1470.2010.01379.x",
language = "English (US)",
volume = "28",
pages = "94--98",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase

T2 - A multicenter retrospective study

AU - Zvulunov, Alex

AU - McCuaig, Catherine

AU - Frieden, Ilona J.

AU - Mancini, Anthony J.

AU - Puttgen, Katherine Brown

AU - Dohil, Magdalene

AU - Fischer, Gayle

AU - Powell, Julie

AU - Cohen, Bernard A

AU - Amitai, Dan Ben

PY - 2011/3

Y1 - 2011/3

N2 - Pharmacological therapies for infantile hemangiomas were considered effective only during the proliferative phases. Recently reported beneficial effects of propranolol may extend beyond the proliferative phase of infantile hemangiomas. The purpose of the study was to assess the effect of oral propranolol therapy for infantile hemangiomas beyond the proliferative phase of these lesions. Members of the Society for Pediatric Dermatology were invited to participate in a multicenter retrospective study. Only children with infantile hemangiomas with documented cessation of lesions' growth or those older than 12 months of age were eligible for the study. Clinical and demographic information and digital photographs before, at the start, and following the treatment were collected. Scaled panels of photographs were distributed among preselected experienced pediatric dermatologists. Visual analog scale was used to assess photographs for each case. Paired t-test was used for statistical analyses. Data on 49 eligible patients from eight pediatric dermatology centers was collected. Seven cases were excluded because of insufficient photographic documentation. The age of the patients at the start of propranolol therapy ranged 7 to 120 months (mean 28 mos, median 22 mos). The duration of propranolol therapy ranged 1 to 8 months (mean 3.6 mos). The mean visual analog scale score before the treatment was 6.8 ± 2.15, and mean reduction in the visual analog scale score at the assessment was 2.6 ± 1.74 (p <0.001). The rate of visual analog scale reduction was 0.4 per month before the start of the therapy, while this rate was accelerated to 0.9 per months following the therapy (p <0.001). No significant side effects were reported. We conclude that propranolol is effective in infantile hemangiomas, including post-proliferative phase, and should be considered as the first-line therapy in that setting.

AB - Pharmacological therapies for infantile hemangiomas were considered effective only during the proliferative phases. Recently reported beneficial effects of propranolol may extend beyond the proliferative phase of infantile hemangiomas. The purpose of the study was to assess the effect of oral propranolol therapy for infantile hemangiomas beyond the proliferative phase of these lesions. Members of the Society for Pediatric Dermatology were invited to participate in a multicenter retrospective study. Only children with infantile hemangiomas with documented cessation of lesions' growth or those older than 12 months of age were eligible for the study. Clinical and demographic information and digital photographs before, at the start, and following the treatment were collected. Scaled panels of photographs were distributed among preselected experienced pediatric dermatologists. Visual analog scale was used to assess photographs for each case. Paired t-test was used for statistical analyses. Data on 49 eligible patients from eight pediatric dermatology centers was collected. Seven cases were excluded because of insufficient photographic documentation. The age of the patients at the start of propranolol therapy ranged 7 to 120 months (mean 28 mos, median 22 mos). The duration of propranolol therapy ranged 1 to 8 months (mean 3.6 mos). The mean visual analog scale score before the treatment was 6.8 ± 2.15, and mean reduction in the visual analog scale score at the assessment was 2.6 ± 1.74 (p <0.001). The rate of visual analog scale reduction was 0.4 per month before the start of the therapy, while this rate was accelerated to 0.9 per months following the therapy (p <0.001). No significant side effects were reported. We conclude that propranolol is effective in infantile hemangiomas, including post-proliferative phase, and should be considered as the first-line therapy in that setting.

UR - http://www.scopus.com/inward/record.url?scp=79954991005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954991005&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1470.2010.01379.x

DO - 10.1111/j.1525-1470.2010.01379.x

M3 - Article

VL - 28

SP - 94

EP - 98

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 2

ER -